DE69924876D1 - Farnesyl protein transferase inhibitoren - Google Patents

Farnesyl protein transferase inhibitoren

Info

Publication number
DE69924876D1
DE69924876D1 DE69924876T DE69924876T DE69924876D1 DE 69924876 D1 DE69924876 D1 DE 69924876D1 DE 69924876 T DE69924876 T DE 69924876T DE 69924876 T DE69924876 T DE 69924876T DE 69924876 D1 DE69924876 D1 DE 69924876D1
Authority
DE
Germany
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
farnesyl
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69924876T
Other languages
English (en)
Other versions
DE69924876T2 (de
Inventor
Timothy Guzi
F Rane
K Mallams
B Cooper
J Doll
M Girijavallabhan
G Taveras
Corey Strickland
M Kelly
Jianping Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69924876D1 publication Critical patent/DE69924876D1/de
Application granted granted Critical
Publication of DE69924876T2 publication Critical patent/DE69924876T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69924876T 1998-12-18 1999-12-16 Farnesyl protein transferase inhibitoren Expired - Fee Related DE69924876T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21656098A 1998-12-18 1998-12-18
US216560 1998-12-18
PCT/US1999/027938 WO2000037458A1 (en) 1998-12-18 1999-12-16 Farnesyl protein transferase inhibitors

Publications (2)

Publication Number Publication Date
DE69924876D1 true DE69924876D1 (de) 2005-05-25
DE69924876T2 DE69924876T2 (de) 2006-03-02

Family

ID=22807539

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924876T Expired - Fee Related DE69924876T2 (de) 1998-12-18 1999-12-16 Farnesyl protein transferase inhibitoren

Country Status (24)

Country Link
EP (1) EP1140904B1 (de)
JP (1) JP2002533335A (de)
KR (1) KR20010081115A (de)
CN (1) CN1285588C (de)
AR (1) AR021716A1 (de)
AT (1) ATE293622T1 (de)
AU (1) AU2347900A (de)
BR (1) BR9916328A (de)
CA (1) CA2354774C (de)
CO (1) CO5160344A1 (de)
CZ (1) CZ20011900A3 (de)
DE (1) DE69924876T2 (de)
ES (1) ES2237963T3 (de)
HK (1) HK1036279A1 (de)
HU (1) HUP0203054A3 (de)
ID (1) ID29065A (de)
IL (1) IL143409A0 (de)
NO (1) NO20012960L (de)
PE (1) PE20001516A1 (de)
PL (1) PL348294A1 (de)
SK (1) SK7582001A3 (de)
TR (1) TR200101754T2 (de)
WO (1) WO2000037458A1 (de)
ZA (1) ZA200104236B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361663B2 (en) 1999-11-10 2008-04-22 Aventis Pharmaceuticals Inc. N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
EP1263726B1 (de) * 1999-11-10 2007-09-26 Sanofi-Aventis Deutschland GmbH N-acylpyrrolidin-2-ylalkylbenzamidin-derivate als inhibitoren von factor xa
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
DE60208157T2 (de) 2001-02-16 2006-08-10 Aventis Pharmaceuticals Inc. Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
CA2509758A1 (en) * 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MX2007007074A (es) 2004-12-13 2007-09-04 Schering Corp Inhibidores novedosos de proteina transferasa de farnesilo y su uso para tratar cancer.
CN101128202A (zh) 2004-12-14 2008-02-20 先灵公司 法呢基蛋白质转移酶抑制剂和用于治疗增殖性疾病的方法
JP2009523799A (ja) * 2006-01-19 2009-06-25 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターとしてのピペラジン誘導体
MX2010012631A (es) * 2008-05-22 2010-12-14 Merck Sharp & Dohme Procedimiento para la preparacion de un antagonista del receptor orexina.
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
GB9420172D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
ATE273299T1 (de) * 1997-06-17 2004-08-15 Schering Corp Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung

Also Published As

Publication number Publication date
CN1352642A (zh) 2002-06-05
CA2354774C (en) 2009-05-26
TR200101754T2 (tr) 2002-05-21
HUP0203054A3 (en) 2004-01-28
KR20010081115A (ko) 2001-08-27
SK7582001A3 (en) 2002-03-05
ZA200104236B (en) 2002-08-23
EP1140904B1 (de) 2005-04-20
ATE293622T1 (de) 2005-05-15
AR021716A1 (es) 2002-07-31
AU2347900A (en) 2000-07-12
EP1140904A1 (de) 2001-10-10
WO2000037458A1 (en) 2000-06-29
ID29065A (id) 2001-07-26
PL348294A1 (en) 2002-05-20
JP2002533335A (ja) 2002-10-08
PE20001516A1 (es) 2001-01-06
BR9916328A (pt) 2001-10-02
NO20012960D0 (no) 2001-06-15
ES2237963T3 (es) 2005-08-01
HK1036279A1 (en) 2001-12-28
NO20012960L (no) 2001-08-15
CZ20011900A3 (cs) 2002-02-13
CA2354774A1 (en) 2000-06-29
HUP0203054A2 (hu) 2003-01-28
DE69924876T2 (de) 2006-03-02
CO5160344A1 (es) 2002-05-30
CN1285588C (zh) 2006-11-22
IL143409A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
NO996571D0 (no) Inhibitorer for farnesyl-protein-transferase
EE04309B1 (et) Farnesüül-proteiini transferaasi inhibiitorid
EE9800408A (et) Proteiinfarnesüültransferaasi inhibiitorid
EE9700314A (et) Farnesüül-proteiini transferaasi inhibiitorid
ATE293622T1 (de) Farnesyl protein transferase inhibitoren
FI951554A0 (fi) Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
NO963860D0 (no) Isoprenyl-transferase-inhibitorer
ATE546139T1 (de) Isoprentransferase proteine inhibitoren
FI952010A (fi) Farnesyyliproteiinitransferaasin estäjät
DK1339695T3 (da) Farnesyltransferase-inhibitorer
NO20012961D0 (no) Trisykliske farnesylproteintransferase-inhibitorer
IS6358A (is) Farnasýl transferasa latar
DE69711081D1 (de) Farnesyl transferase inhibitoren
ATE371655T1 (de) Farnesyl-protein-transferaseinhibitoren
DK1087981T3 (da) Prenyltransferaseinhibitorer
NO20022923D0 (no) Inhibitorer av farnesyl-protein-transferase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee